Shares of Cannabis Science Inc. (OTC: CBIS), a development-stage company engaged in the development of pharmaceutical grade medical cannabis products, fell in Monday’s trading session. CBIS shares ended the day 3.03% lower at $0.0800. The stock is down more than 43% in the last one month.
Earlier this month, Cannabis Science announced that it is teaming with Dr. Ivan Goldsmith of Trimcare in Las Vegas for innovative weight loss programs based on research of the endocannabinoid system.
Dr. Goldsmith and CBIS have teamed up to implement novel treatments for obesity, metabolic syndrome, and hormone deficiency syndromes. Dr. Goldsmith’s Trimcare focuses on cosmetic procedures, a unique diet based on the patient’s DNA and customized to the patient’s genotype.
Although Cannabis Science has made some decent progress, the medical cannabis industry remains highly controversial. However, earlier this month, House Minority Leader Nancy Pelosi supported the industry in statement to President Obama.
Dr. Robert Melamede, CEO of Cannabis Science, said earlier this month that he expects to continue to see more politicians come out in favor of the medical cannabis industry over the next few months.
Recent Comments